엔케이맥스&nbsp;주가가&nbsp;장&nbsp;초반&nbsp;큰&nbsp;폭으로&nbsp;오르고&nbsp;있다.<br /> <br /> 엔케이맥스가&nbsp;개발하고&nbsp;있는&nbsp;자연살해(NK)세포치료제를&nbsp;향한&nbsp;기대감이&nbsp;이어지는&nbsp;것으로&nbsp;풀이된다.<br /> &nbsp; <figure class="image" style="float:right;margin-right:0px; margin-left:15px; margin-top:30px; "><img alt="엔케이맥스 주가 초반 급등, 자연살해세포치료제 개발 기대 지속 " height="200" class='lazyload' data-src="https://www.businesspost.co.kr/news/photo/202108/20210831104013_58100.jpeg" width="300" /> <figcaption><table width=320><tr><td align='left' style='margin:0; padding:0px 0px; color:#306f7f; font-size:12px; font-family:verdana; letter-spacing:-0.1em; line-height:160%; table-layout: fixed; width:180px;'>▲ 엔케이맥스 로고.</td></tr></table></figcaption> </figure> <br /> 31일&nbsp;오전&nbsp;9시57분&nbsp;기준&nbsp;엔케이맥스&nbsp;주가는&nbsp;전날보다&nbsp;14.77%(2400원)&nbsp;뛴&nbsp;1만8650원에&nbsp;거래되고&nbsp;있다.<br /> <br /> 엔케이맥스는&nbsp;미국에서&nbsp;불응성&nbsp;고형암환자&nbsp;27명을&nbsp;대상으로&nbsp;자연살해(NK)세포&nbsp;치료제의&nbsp;임상1상을&nbsp;진행하고&nbsp;있다.<br /> <br /> 최근&nbsp;발표한&nbsp;중간결과에&nbsp;따르면&nbsp;말기&nbsp;1명의&nbsp;환자에게서&nbsp;완전관해&nbsp;반응이&nbsp;나왔다.&nbsp;완전관해는&nbsp;몸에서&nbsp;암세포가&nbsp;완전히&nbsp;사라지는&nbsp;것을&nbsp;뜻한다.<br /> <br /> 엔케이맥스는&nbsp;기존약물로&nbsp;치료가&nbsp;불가능한&nbsp;수준의&nbsp;육종암&nbsp;말기&nbsp;암환자&nbsp;13명에&nbsp;대한&nbsp;분석결과를&nbsp;발표했다.<br /> <br /> 13명&nbsp;가운데&nbsp;8명이&nbsp;치료효과를&nbsp;보였다.&nbsp;암세포가&nbsp;대부분&nbsp;제거된&nbsp;완전관해 1명,&nbsp;암세포가&nbsp;30%이상&nbsp;감소한&nbsp;부분관해&nbsp;2명,&nbsp;암세포가&nbsp;증가하지&nbsp;않은&nbsp;안전병변&nbsp;5명&nbsp;등이다.<br /> <br /> 엔케이맥스&nbsp;관계자는&nbsp;&ldquo;이번&nbsp;결과는&nbsp;NK세포를&nbsp;이용한&nbsp;고형암&nbsp;임상에서&nbsp;세계&nbsp;최초의&nbsp;결과이며&nbsp;악성종양인&nbsp;육종암에서&nbsp;완전관해라는&nbsp;결과가&nbsp;나온&nbsp;것은&nbsp;NK세포치료법&nbsp;개발의&nbsp;중요한&nbsp;성과&rdquo;라고&nbsp;말했다.&nbsp;[비즈니스포스트 박안나 기자]